Trial Profile
A Phase I, first-in-human trial of GSK2126458 (GSK458) in patients with advanced solid tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Omipalisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 07 Dec 2015 New trial record
- 24 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research